Cohance Lifesciences Limited (BOM:543064)

Market Cap	120.74B -51.9%
Revenue (ttm)	10.58B +0.9%
Net Income	606.40M -78.3%
EPS	2.35 -78.5%
Shares Out	n/a
PE Ratio	199.11
Forward PE	32.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154,342
Average Volume	37,379
Open	321.45
Previous Close	350.60
Day's Range	311.15 - 340.45
52-Week Range	311.15 - 1,328.20
Beta	n/a
RSI	18.65
Earnings Date	Feb 12, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,212
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In fiscal year 2025, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.